FIS
ENGNW icon

FCPM III Services’s enGene Therapeutics Warrants ENGNW Stock Holding History

FCPM III Services’s Portfolio ENGNW Stock Details ENGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.28M Hold
2,878,148
– – 1.01% 10
2025
Q4 		$8.52M Hold
2,878,148
– – 1.12% 10
2025
Q3 		$2.07M Hold
2,878,148
– – 0.41% 9
2025
Q2 		$2.36M Hold
2,878,148
– – 0.64% 8
2025
Q1 		$1.73M Hold
2,878,148
– – 0.42% 7
2024
Q4 		$2.43M Hold
2,878,148
– – 0.41% 8
2024
Q3 		$6.04M Hold
2,878,148
– – 1.04% 6
2024
Q2 		$3.42M Hold
2,878,148
– – 0.51% 6
2024
Q1 		$15M Sell
2,878,148
-1,000,000
-26% -$3.05M 2.12% 5
2023
Q4 		$2.45M Buy
+3,878,148
New +$2.98M 0.72% 5

Other funds holding ENGNW

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

FCPM III Services's ENGNW Position: Q1 2026 in Review

FCPM III Services held its enGene Therapeutics Warrants (ENGNW) position steady in Q1 2026 at 2,878,148 shares worth $7.28M. The position accounts for 1.01% of the portfolio, ranked #10.

FCPM III Services first reported a position in ENGNW in Q4 2023 and has held it in 10 quarters since. The position peaked at $15M in Q1 2024. 11 funds tracked by Wall St. Rank hold ENGNW as of Q1 2026.

  • FCPM III Services held 2,878,148 shares of enGene Therapeutics Warrants worth $7.28M as of Q1 2026.
  • FCPM III Services left its enGene Therapeutics Warrants share count unchanged in Q1 2026.
  • enGene Therapeutics Warrants made up 1.01% of FCPM III Services's portfolio in Q1 2026, its #10 holding.
  • FCPM III Services first reported a position in enGene Therapeutics Warrants in Q4 2023 and has held it in 10 quarters since.
  • FCPM III Services's enGene Therapeutics Warrants position peaked at $15M in Q1 2024.
  • 11 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q1 2026.

Based on FCPM III Services's 13F filing for Q1 2026, filed 15 May 2026.